Table 1. Characteristics of the included studies.

Study	Year	TP	FP	FN	TN	Patient	Nation	Patient Spectrum*	Study design	blind	Method
Schreiter [16]	2012	99	4	14	26	143	Germany	liver metastases	prospective	Y	1.5T
Goshima [17]	2010	28	4	1	28	61	Japan	liver metastases	retrospective	Y	3.0T
Kim [18]	2010	75	2	6	16	99	Korea	liver metastases	retrospective	Y	1.5T
Lee, M [19]	2011	78	2	1	37	118	Korea	liver metastases	retrospective	Y	3.0T
Shimada [20]	2010	48	2	4	52	106	Japan	liver metastases	retrospective	Y	3.0T
Chung [23]	2011	77	5	2	29	113	Korea	CRLM	retrospective	Y	3.0T
Sofue [22]	2011	81	5	7	51	144	Japan	CRLM	retrospective	Y	3.0T
Kulemann [21]	2011	45	0	6	13	64	Austria	CRLM	retrospective	Y	1.5/3.0T
Muhi, A [24]	2011	56	1	3	206	266	Japan	liver metastases	retrospective	Y	1.5T
Motosugi [25]	2011	48	3	10	45	106	Japan	CRLM	retrospective	Y	1.5T
Lowenthal [26]	2010	268	2	10	52	332	Germany	liver metastases	retrospective	Y	1.5T
Donati [29]	2010	50	0	5	30	85	Switzerland	CRLM	retrospective	Y	1.5T
Seo [30]	2011	123	2	12	28	165	Korea	CRLM	retrospective	Y	3.0T

^*CRLM  =  colorectal liver metastases.